TNF Pharmaceuticals, Inc. (TNFA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TNF Pharmaceuticals, Inc. (TNFA) has a cash flow conversion efficiency ratio of -0.178x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.07 Million) by net assets ($11.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TNF Pharmaceuticals, Inc. (TNFA) market capitalisation for the company's overall valuation and market capitalisation.
TNF Pharmaceuticals, Inc. - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how TNF Pharmaceuticals, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
TNF Pharmaceuticals, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TNF Pharmaceuticals, Inc. ranked by their cash flow conversion efficiency. Explore TNF Pharmaceuticals, Inc. (TNFA) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kumpulan Jetson Bhd
KLSE:9083
|
0.081x |
|
DGB Group NV
AS:DGB
|
0.235x |
|
PT Sunter Lakeside Hotel Tbk
JK:SNLK
|
0.004x |
|
Bell Copper Corp
V:BCU
|
-0.066x |
|
IL&FS Transportation Networks Limited
NSE:IL&FSTRANS
|
0.000x |
|
Corella Resources Ltd
AU:CR9
|
-0.129x |
|
Longvie SA
BA:LONG
|
-0.060x |
|
Micro Digital Co. Ltd
KQ:305090
|
-0.143x |
Annual Cash Flow Conversion Efficiency for TNF Pharmaceuticals, Inc. (2004–2024)
The table below shows the annual cash flow conversion efficiency of TNF Pharmaceuticals, Inc. from 2004 to 2024. View TNF Pharmaceuticals, Inc. (TNFA) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.72 Million | $-8.98 Million | -0.610x | +39.99% |
| 2023-12-31 | $12.77 Million | $-12.98 Million | -1.016x | -21.70% |
| 2022-12-31 | $14.70 Million | $-12.27 Million | -0.835x | -1.17% |
| 2021-12-31 | $23.65 Million | $-19.52 Million | -0.825x | -511.96% |
| 2020-12-31 | $34.58 Million | $-4.66 Million | -0.135x | +58.96% |
| 2019-12-31 | $9.36 Million | $-3.07 Million | -0.329x | +77.49% |
| 2018-12-31 | $5.83 Million | $-8.52 Million | -1.460x | -117.05% |
| 2017-12-31 | $7.55 Million | $-5.08 Million | -0.673x | +45.40% |
| 2016-12-31 | $3.39 Million | $-4.17 Million | -1.232x | -58.49% |
| 2015-12-31 | $6.60 Million | $-5.13 Million | -0.777x | -196.31% |
| 2014-12-31 | $14.81 Million | $-3.88 Million | -0.262x | +60.39% |
| 2013-12-31 | $4.12 Million | $-2.73 Million | -0.662x | -173.81% |
| 2012-12-31 | $4.30 Million | $-1.04 Million | -0.242x | +34.04% |
| 2011-12-31 | $6.17 Million | $-2.26 Million | -0.367x | -36.69% |
| 2010-12-31 | $6.45 Million | $-1.73 Million | -0.268x | -39.14% |
| 2009-12-31 | $7.18 Million | $-1.38 Million | -0.193x | -522.17% |
| 2008-12-31 | $10.28 Million | $469.37K | 0.046x | +111.11% |
| 2007-12-31 | $-443.38K | $182.19K | -0.411x | -120.67% |
| 2006-12-31 | $-2.67 Million | $-5.31 Million | 1.988x | +210.63% |
| 2005-12-31 | $3.12 Million | $-5.61 Million | -1.797x | -222.55% |
| 2004-12-31 | $-2.79 Million | $-4.10 Million | 1.466x | -- |
About TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more